The current price of PDSB is $1.23 — it has increased by 5.13% since the previous close. Data as of Nov 6, 2026.
PDSB is down 17.45% over the past week, up 14.95% over the past month and up 35.08% over the past year. The price is above its 200-day moving average of $0.8382.
Analysts' average 12-month price target for PDSB is $4.00, which implies 225.20% upside from the current price. Individual estimates range from $4.00 to $4.00.
Of the 2 analysts covering PDS Biotechnology Corporation, 2 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
PDS Biotechnology Corporation has a market capitalization of $68.65M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, PDS Biotechnology Corporation posted a loss of $0.18 per share against an estimate of -$0.13, missing expectations by 38.46%. Upcoming reports are listed in the earnings calendar.
PDS Biotechnology Corporation has not paid any dividends over the past year.
In the latest trading session PDSB moved between $1.18 and $1.27, a range of 7.32% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of PDS Biotechnology Corporation shows a buy rating today and a buy rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks PDSB has traded between $0.1952 and $1.79. The current price is 31.28% below its 52-week high.
Figures as of Nov 6, 2026. This information is provided for general purposes only and is not investment advice.